STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

March 31, 2004

Study Completion Date

March 31, 2005

Conditions
Stage IIIB Non-Small Cell Lung CancerStage IV Non-Small Cell Lung Cancer
Interventions
DRUG

Paclitaxel

DRUG

Carboplatin

DRUG

STA 4783

Trial Locations (19)

21236

Maryland Hematology and Oncology Associates, Baltimore

34236

Oncology Hematology Consultants, Sarasota

37203

The Sarah Cannon Research Center, Nashville

38120

The West Clinic, Memphis

55805

The Duluth Clinic, Duluth

60007

The Cancer Institute at Alexian Brothers, Elk Grove Village

60426

Ingalls Hospital, Harvey

60637

University of Chicago, Chicago

71101

Overton Brooks, VAMC, Shreveport

71130

LSUHSC - Shreveport Feist Weiller Cancer Center, Shreveport

72401

NEA Clinic, Jonesboro

75231

Presbyterian Hospital, Dallas

90404

Cancer Institute Medical Group, Santa Monica

91767

Wilshire Oncology Medical Group, Pomona

98405

Multicare Health System, Tacoma

Unknown

St. Francis Memorial Hospital, San Francisco

Kaiser Permanete, Vallejo

ACORN, Miami

06611

Oncology Associates of Bridgeport, Trumball

All Listed Sponsors
lead

Synta Pharmaceuticals Corp.

INDUSTRY

NCT00088088 - STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter